Why the study?
Microvascular resistance reserve (MRR) was introduced to characterize coronary microcirculation vasodilator capacity accounting for epicardial disease and aortic pressure changes, but its diagnostic and prognostic performance needed evaluation.
Does microvascular resistance reserve (MRR) predict major adverse cardiac events and target vessel failure in patients with stable symptoms undergoing coronary angiography?
Population
1481 patients with stable symptoms and indication for coronary angiography
Comparison
MRR vs CFR across different FFR values
Design
Registry-based cohort study
Follow-up
5 years
Key result
Microvascular resistance reserve (MRR) was independently associated with major adverse cardiac events (MACE) at 5 years (HR 0.78) in patients with significant epicardial disease.
Authors
Loading...
MRR may refine prognostication in stable CAD with epicardial disease; hypothesis-generating and should not yet change practice.
Does microvascular resistance reserve (MRR) predict major adverse cardiac events and target vessel failure in patients with stable symptoms undergoing coronary angiography?
MRR is a robust indicator of microvascular vasodilator reserve capacity and independently predicts 5-year MACE and TVF, offering a diagnostic advantage in patients with hemodynamically significant epicardial coronary artery disease.
Boerhout et al. (2023) studied this question. Microvascular resistance reserve (MRR) was independently associated with major adverse cardiac events (MACE) at 5 years (HR 0.78) in patients with significant epicardial disease.